News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Plus, America’s big cities are rapidly losing kids, and Trump puts off a major escalation of his military campaign against Iran.
Stocks looked set to rally on Monday as oil prices retreated, helping to ease investors’ worries about higher inflation at the start of a week that will be defined by a Federal Reserve policy decision and a slew of mega-cap tech earnings. Nasdaq 100 futures jumped 1.4%. The three major indexes all dropped last week as tensions flared in the Middle East, driving up oil prices and bolstering the case for the Fed to hike interest rates.
This year’s stock rally has withstood war, inflation and uncertainty surrounding the tech sector’s massive artificial-intelligence investments. The question now is: Have investors finally reached their limit? Major stock indexes have posted healthy gains this year.
Iran and Oman are also in talks that center around having Iran run vessel transit through the Strait of Hormuz with fewer restrictions on ships.
This is a huge earnings week, with nearly a third of S&P 500 companies reporting. The Fed is expected to hold rates steady after its confab ends Wednesday, and we’ll see key inflation data on Thursday.

Investors step into the busiest week of the quarter with hyperscaler earnings, the June Fed meeting, and escalations in the Middle East all in focus.
There's more to Trumpflation than just higher energy prices.
If you think the worst is over for inflation, you're about to be sorely mistaken.
Dow Jones futures will open Sunday evening, along with S&P 500 futures and Nasdaq futures. Apple, Microsoft, Meta Platforms, Amazon.com headline a massive earnings wave. The Federal Reserve meets, with a rate hike a possibility.
President Trump has proposed new tariffs on roughly 60 countries, adding another layer of uncertainty for investors. On today's Opening Bid panel, featuring Robinhood (HOOD) chief investment officer Stephanie Guild and Miller Tabak managing director and equity strategist Matt Maley, join Executive Editor Brian Sozzi to discuss investment opportunities and portfolio positioning as markets rotate in response to shifting trade policy and broader macroeconomic trends.
July 24 (Reuters) - Wall Street's main indexes opened subdued on Friday after a tech-led selloff in the previous session, as investors digested fresh earnings, escalating Middle East tensions and a
(Bloomberg) -- Corporate earnings strong enough to beat the highest expectations in years have failed to impress investors fretting about AI spending and economic growth.Most Read from BloombergRetina Chip Designed to Restore Sight to Go on Sale in EuropeHegseth Turns to UNC, Virginia Tech After Dropping Ivy LeagueApple Plans Overhaul of MacBooks, iMac in Push to Meet AI DemandTrump Rebuilds Tariffs With New Levies on 60 EconomiesAlphabet Falls as $205 Billion Spending Plan Fuels AI Cost FearAbo
US equity futures nudged higher pre-bell Friday as traders weighed a new set of tariffs imposed by t
U. S. stock futures edged higher on Friday as investors balanced escalating geopolitical tensions in the Middle East against encouraging corporate earnings from the technology sector.
Stocks looked set to struggle for direction on Friday as a drop in oil prices eased fears about higher inflation, even as artificial-intelligence jitters lingered. Nasdaq 100 futures rose 0.1%. The Dow was on track to outperform the other two major indexes because it tends to be more reactive to oil prices, which were retreating having spiked above $100 a barrel the previous session.
Stocks stabilized on Friday but were on track for weekly losses as investors assessed a new set of global tariffs against a backdrop of AI jitters, rising oil prices, and elevated bond yields.

<body><p>STORY: Wall Street stocks plummeted on Thursday, with the Dow dropping about 1%, the S&P 500 shedding 1.2% and the Nasdaq tumbling more than 2%.</p><p>The latest earnings results from large tech companies such as Alphabet and Tesla revived concerns about heavy AI spending, says Keith Buchanan, senior portfolio manager for Globalt Investments.</p><p>"We're at a point now where the hype has to kind of meet some level of realistic expectation, quantifiable expectation. And the markets are starting to digest just what this means to cash flow in some of the largest companies in the world going forward. And a lot of spending is eating into cash flow in a way that's making investors lose a bit of comfort and question a lot of valuations that have grown over the past couple of years. And that's what's really at the root of what's really hampering some of the market returns today and giving back some of the gains that we've gotten for the market over the past couple of weeks."</p><p>Shares of Alphabet sank 7% after the tech giant reported higher spending plans while it also burned cash.</p><p>And shares of Tesla tumbled 14.5% after Elon Musk's EV maker reported negative free cash flow in the second quarter for the first time in more than two years.</p><p>But shares of Intel rose 10% in extended trading after the company forecast quarterly profit and revenue above Wall Street estimates as an AI data center buildout increases demand for its central processing units, or CPUs.</p><p>Meanwhile, Brent crude oil futures settled above $100 a barrel for the first time since May, and U.S. oil futures settled above $92.</p><p>The surge in oil prices prompted worries about inflation ahead of next week's Federal Reserve policy meeting.</p></body>
Federal debt has surpassed a threshold not crossed since World War II, and the troubling part is not where it stands today but where it is headed and what that means for your portfolio before the next recession arrives.
Drugmaker Eli Lilly said Thursday that it is on track to seek federal approval for its next-generation obesity drug early next year. Lilly became the first drug company to reach a trillion dollar valuation last fall as sales of its weight loss drugs took off. Among adults with general obesity, the weekly injectable lowered the weight of late-stage trial participants by an average of 28% over 80 weeks at the highest doses tested.